v-safe接种后健康检查器:CDC新冠疫情期间的主动疫苗安全监测
美国CDC开发并实施v-safe接种后健康检查器,作为现有疫苗安全监测项目的主动监测补充。2020年12月14日至2021年12月13日期间,9,342,582人提交了131,543,087份v-safe调查;参与者多数为女性(62.3%)和非西班牙裔白人(61.2%),中位年龄49.0岁,95.0%报告首剂接种mRNA新冠疫苗。v-safe为FDA授权新冠疫苗的近实时反应原性报告、疫苗不良事件报告系统报告促进及大型接种后妊娠登记入组提供了支持。
要点
- v-safe通过短信链接至网络健康检查调查,在接种后每日、每周和每月时间点收集症状及健康影响。
- 2020年12月14日至2021年12月13日,9,342,582人提交131,543,087份v-safe调查。
- 参与者62.3%为女性,61.2%为非西班牙裔白人,中位年龄49.0岁,95.0%首剂为mRNA新冠疫苗。
核心结论
- v-safe通过实现近实时反应原性报告、促进向疫苗不良事件报告系统报告及协助大型接种后妊娠登记入组,为CDC对FDA授权新冠疫苗的安全性评估做出了贡献。
- 作者认为,鉴于v-safe是美国历史上最全面的安全监测项目的组成部分,该方法有望作为未来大流行应对活动及非大流行背景下新疫苗推广的潜在应用。
研究设计与样本
- 美国CDC开发并实施v-safe接种后健康检查器,作为现有CDC疫苗安全监测项目的主动监测补充。
- v-safe允许接种新冠疫苗者报告接种后体验及症状对健康的影响,时间点为接种后每日、每周和每月。
- 系统发送短信提醒链接至网络健康检查调查,调查包含问题以识别可能符合条件入组独立妊娠登记活动的v-safe参与者,该活动评估接种时妊娠或围受孕期间接种者的母婴结局。
- 本文描述v-safe的开发与改进、数据管理、对接种点和合作伙伴的推广与沟通、出版物、优势与局限性及对未来系统的启示,并描述运营第一年(2020年12月14日至2021年12月13日)的入组情况和参与者人口学特征。
主要发现
- 2020年12月14日至2021年12月13日期间,9,342,582人提交了131,543,087份v-safe调查。
- 参与者大多数为女性(62.3%)和非西班牙裔白人(61.2%);中位年龄为49.0岁。
- 大多数参与者报告首剂记录接种mRNA新冠疫苗(95.0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Centers for Disease Control and Prevention (CDC) developed and implemented the v-safe after vaccination health checker (v-safe) to monitor COVID-19 vaccine safety and as an active surveillance supplement to existing CDC vaccine safety monitoring programs. V-safe allows persons who received COVID-19 vaccines to report on post-vaccination experiences and how symptoms affected their health at daily, weekly, and monthly timepoints after vaccination. Text message reminders are sent linking to Internet-based health check-in surveys. Surveys include questions to identify v-safe participants who may be eligible to enroll in a separate pregnancy registry activity that evaluates maternal and infant outcomes in those pregnant at the time of vaccination or receiving vaccine in the periconception period. We describe the development of and enhancements to v-safe, data management, promotion and communication to vaccination sites and partners, publications, strengths and limitations, and implications for future systems. We also describe enrollment in v-safe over time and demographics of persons participating in v-safe during the first year of operation (December 14, 2020 - December 13, 2021). During this time, 9,342,582 persons submitted 131,543,087 v-safe surveys. The majority of participants were female (62.3 %) and non-Hispanic White (61.2 %); median age was 49.0 years. Most participants reported receiving an mRNA COVID-19 vaccine as their first recorded dose (95.0 %). V-safe contributed to CDC's vaccine safety assessments for FDA-authorized COVID-19 vaccines by enabling near real-time reporting of reactogenicity once the COVID-19 vaccination program began in the community, encouraging reports to the Vaccine Adverse Event Reporting System and facilitating enrollment in a large post-vaccination pregnancy registry. Given that v-safe is an integral component of the most comprehensive safety monitoring program in U.S. history, we believe that this approach has promise as a potential application for future pandemic response activities as well as rollout of novel vaccines in a non-pandemic context.
引用
- Myers TR, Marquez PL, Gee JM, et al. The v-safe after vaccination health checker: Active vaccine safety monitoring during CDC's COVID-19 pandemic response. Vaccine. 2023. PMID: 36697313. doi:10.1016/j.vaccine.2022.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。